Attrition in the Pharmaceutical Industry
Reasons, Implications, and Pathways Forward
Compound attrition in drug discovery and development is one of the major challenges the pharmaceutical industry has faced over the last two decades, with an insufficient number of revenue-generating new drugs in recent years leading to misaligned investments in research and development. Additionally, the value of existing data and knowledge has been neglected - leading to insufficient learning from drug programs and inevitable repeat of poor results. A further reluctance to utilize new technologies, like advances in IT and data management, has led to many companies being unable to convert data archives into useful knowledge to improve product…
Mehr
CHF 99.00
Preise inkl. MwSt. und Versandkosten (Portofrei ab CHF 40.00)
Versandkostenfrei
Produktdetails
Weitere Autoren: Harris, C. John / Alex, Alexander
- ISBN: 978-1-118-81944-9
- EAN: 9781118819449
- Produktnummer: 19073323
- Verlag: Wiley
- Sprache: Englisch
- Erscheinungsjahr: 2015
- Seitenangabe: 352 S.
- Plattform: PDF
- Masse: 6'216 KB
Über den Autor
Alexander Alex, Dr. rer. nat., is director of Evenor Consulting and has over 20 years' experience as consultant and as director and research fellow in drug discovery in the pharmaceutical industry.C. John Harris, PhD, is the director of cjh Consultants and has a successful track record in drug discovery, research management, small company fund-raising and start-ups.Dennis A. Smith, PhD, is an independent consultant with a long track record in drug discovery and development with an emphasis on metabolism and safety. He has published four books, including Pharmacokinetics and Metabolism in Drug Design (1st and 2nd editions) and Reactive Drug Metabolites published by Wiley.
13 weitere Werke von Dennis A. Smith:
Bewertungen
Anmelden